Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Volanesorsen
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Brazilian Regulatory Authority Grants Approval for Waylivra™ for Familial Partial Lipodystrophy
Details : Waylivra (volanesorsen), an antisense oligonucleotide designed to inhibit the formation of apoC-III, is a product of Ionis Pharmaceuticals, Inc.'s proprietary antisense technology. Waylivra has received conditional marketing approval in the EU as a treat...
Brand Name : Waylivra
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 01, 2022
Lead Product(s) : Volanesorsen
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?